Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital

Eyob Alemayehu Gebreyohannes, Akshaya Srikanth Bhagavathula, Tamrat Befekadu Abebe, Yonas Getaye Tefera, Tadesse Melaku Abegaz, Eyob Alemayehu Gebreyohannes, Akshaya Srikanth Bhagavathula, Tamrat Befekadu Abebe, Yonas Getaye Tefera, Tadesse Melaku Abegaz

Abstract

Background: A considerable proportion of cardiovascular events could be attributed to poor adherence to antihypertensive medications. Adverse effects can be severe enough to affect adherence to antihypertensive medications. This study aimed to measure the contribution of adverse effects on antihypertensive medications adherence.

Methods: The study was conducted from May 1 to June 30, 2017, at the ambulatory clinic of University of Gondar Comprehensive Specialized Hospital (UOGCSH) in Gondar town. A binary logistic regression was performed to determine the significance of the association between adverse effects and adherence to antihypertensive medications. An institution-based cross-sectional study was conducted by administering a questionnaire to hypertensive patients who came for follow-up at the ambulatory clinic of UOGCSH. Level of adherence to antihypertensive medications was used as outcome measure.

Results: A total of 249 patients were included in the final analysis with a mean age of 56.51 years and a female majority (53%). The following variables were identified as predictors of poor adherence: tiredness [AOR (95% CI): 3.802 (1.723-8.391), p = 0.001], muscle pain [AOR (95% CI): 5.199 (1.407-19.214), p = 0.013], poor sleep [AOR (95% CI): 4.891 (1.578-15.160), p = 0.006] and, believing that the symptoms were caused by antihypertensive medications [AOR (95% CI): 3.249 (1.248-8.456), p = 0.016].

Conclusion: Adverse effect significantly contributes to antihypertensive medication non-adherence among hypertensive patients.

Keywords: Adherence; Adverse effects; Antihypertensive medications; Ethiopia; Gondar; Hypertension.

Conflict of interest statement

Ethical clearance was obtained from the research ethical review committee of the school of Pharmacy, University of Gondar. Written informed consent was sought from each study participant and confidentiality of the information was assured in such a way that no disclosure of any information obtained from the participants in relation to the finding was made and the information was used for the research purpose only.Not applicable.The authors’ declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
The number of hypertensive patients using different antihypertensive medications at UOGCSH (N = 249)

References

    1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2571. doi: 10.1001/jama.289.19.2560.
    1. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–2948. doi: 10.1093/eurheartj/eht295.
    1. Dragomir A, Côté R, Roy L, Blais L, Lalonde L, Bérard A, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5):418–425. doi: 10.1097/MLR.0b013e3181d567bd.
    1. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. 2007 Available from: . [Cited 4 August 2017]
    1. World Health Organization. A global brief on hypertension: silent killer, global public health crisis. 2013. Available from: . [Cited 4 August 2017]
    1. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91. doi: 10.3389/fphar.2013.00091.
    1. Shin S, Song H, Oh S-K, Choi KE, Kim H, Jang S. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients. Hypertens Res. 2013;36(11):1000–1005. doi: 10.1038/hr.2013.85.
    1. Lowry KP, Dudley TK, Oddone EZ, Bosworth HB. Intentional and unintentional nonadherence to antihypertensive medication. Ann Pharmacother. 2005;39(7–8):1198–1203. doi: 10.1345/aph.1E594.
    1. Black H, Graff A, Shute D, Stoltz R, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997;11(8):483–489. doi: 10.1038/sj.jhh.1000482.
    1. Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985;253(22):3263–3268. doi: 10.1001/jama.1985.03350460063022.
    1. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2008;14(3):181–188. doi: 10.1016/j.cardfail.2007.11.008.
    1. Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499–509. doi: 10.1111/j.1365-2753.2003.00484.x.
    1. Bardage C, Isacson DG. Self-reported side-effects of antihypertensive drugs: an epidemiological study on prevalence and impact on health-state utility. Blood Press. 2000;9(6):328–334. doi: 10.1080/080370500300000905.
    1. Düsing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy-the role of adverse effects and compliance. Blood Press. 1998;7(5–6):313–315.
    1. Fletcher AE, Bulpitt CJ, Chase DM, Collins WC, Furberg CD, Goggin TK, et al. Quality of life with three antihypertensive treatments. Cilazapril Atenolol Nifedipine Hypertension. 1992;19(6 Pt 1):499–507. doi: 10.1161/01.HYP.19.6.499.
    1. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med. 1992;117(3):234–242. doi: 10.7326/0003-4819-117-3-234.
    1. MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3(4):193–217. doi: 10.1002/j.1875-9114.1983.tb03252.x.
    1. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep. 2002;4(6):479–482. doi: 10.1007/s11886-002-0110-9.
    1. Olsen H, klemetsrud T, Stokke HP, Tretli S, Westheim A. Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway. Blood Press. 1999;8(2):94–101. doi: 10.1080/080370599438266.
    1. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al. A comparison of the efficacy and safety of a β-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150(8):1707–1713. doi: 10.1001/archinte.1990.00040031707020.
    1. Fodor GJ, Kotrec M, Bacskai K, Dorner T, Lietava J, Sonkodi S, et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study. J Hypertens. 2005;23(6):1261–1266. doi: 10.1097/.
    1. Ambaw AD, Alemie GA, Mengesha ZB. Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC Public Health. 2012;12(1):282. doi: 10.1186/1471-2458-12-282.
    1. Duarte-Silva D, Figueiras A, Herdeiro MT, Rodrigues AT, Branco FS, Polonia J, et al. PERSYVE-design and validation of a questionnaire about adverse effects of antihypertensive drugs. Pharm Pract. 2014;12(2):396.
    1. Al-Ramahi R. Adherence to medications and associated factors: a cross-sectional study among Palestinian hypertensive patients. J Epidemiol Glob Health. 2015;5(2):125–132. doi: 10.1016/j.jegh.2014.05.005.
    1. Ghembaza M, Senoussaoui Y, Kendouci Tani M, Meguenni K. Impact of patient knowledge of hypertension complications on adherence to antihypertensive therapy. Curr Hypertens Rev. 2014;10(1):41–48. doi: 10.2174/157340211001141111160653.
    1. Grassi G, Seravalle G, Mancia G. Cardiovascular consequences of poor compliance to antihypertensive therapy. Blood Press. 2011;20(4):196–203. doi: 10.3109/08037051.2011.557902.
    1. Nuesch R, Schroeder K, Dieterle T, Martina B, Battegay E. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. BMJ. 2001;323(7305):142–146. doi: 10.1136/bmj.323.7305.142.
    1. AlGhurair SA, Hughes CA, Simpson SH, Guirguis LM. A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the World Health Organization multidimensional adherence model. J Clin Hypertens. 2012;14(12):877–886. doi: 10.1111/j.1751-7176.2012.00699.x.
    1. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19(11):1190–1196. doi: 10.1016/j.amjhyper.2006.04.006.
    1. Dharmarajan TS, Dharmarajan L. Tolerability of antihypertensive medications in older adults. Drugs Aging. 2015;32(10):773–796. doi: 10.1007/s40266-015-0296-3.
    1. Grégoire J-P, Moisan J, Guibert R, Ciampi A, Milot A, Gaudet M, et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol. 2002;55(7):728–735. doi: 10.1016/S0895-4356(02)00400-6.
    1. Hong TB, Oddone EZ, Dudley TK, Bosworth HB. Medication barriers and anti-hypertensive medication adherence: the moderating role of locus of control. Psychol Health Med. 2006;11(1):20–28. doi: 10.1080/14786430500228580.
    1. Marshall IJ, Wolfe CD, McKevitt C. Lay perspectives on hypertension and drug adherence: systematic review of qualitative research. BMJ. 2012;345:e3953. doi: 10.1136/bmj.e3953.
    1. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004;2:CD004804.
    1. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure–lowering medication in ambulatory care?: systematic review of randomized controlled trials. Arch Intern Med. 2004;164(7):722–732. doi: 10.1001/archinte.164.7.722.
    1. Handler J. Quality of life and antihypertensive drug therapy. J Clin Hypertens. 2005;7(5):274–285. doi: 10.1111/j.1524-6175.2005.04470.x.
    1. Morgado M, Morgado S, Mendes L, Pereira L, Castelo Branco M. Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: review and meta-analysis. AJHP. 2011;68:241–253.
    1. Rake EC, Breeze E, Fletcher AE. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo. J Hum Hypertens. 2001;15(12):863. doi: 10.1038/sj.jhh.1001283.
    1. Breeze E, Rake EC, Donoghue MD, Fletcher AE. Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension. J Hum Hypertens. 2001;15(12):857. doi: 10.1038/sj.jhh.1001282.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe